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The N-terminal cytoplasmic domain of the anion ex-
changer 1 (AE1 or band 3) of the human erythrocyte
associates with peripheral membrane proteins to regu-
late membrane-cytoskeleton interactions, with glyco-
lytic enzymes such as glyceraldehyde-3-phosphate dehy-
drogenase and aldolase, with the protein-tyrosine
kinase p72syk, with hemoglobin and with hemichromes.
We have demonstrated that the N-terminal cytoplasmic
domain of band 3 (CDB3) is a substrate of the apoptosis
executioner caspase 3 (1). CDB3 has two non-conven-
tional caspase 3 cleavage sites, TATD45 and EQGD205 (2).
In vitro treatment of recombinant CDB3 with caspase 3
generated two fragments, which could be blocked by
pretreatment with the caspase 3 inhibitor Z-DEVD-fmk
(3). Recombinant CDB3 in which the caspase 3 cleavage
sites Asp45 and Asp205 were mutated, was resistant to
proteolysis (4). Proteolytically derived fragments cross-
reactive with polyclonal anti-band 3 antibody appeared
with simultaneous cleavage of poly (ADP-ribose) polym-
erase and procaspase 3 in staurosporine (STS)-treated
HEK293 cells transiently transfected with CDB3 (5). In
vivo cleavage of CDB3 could be blocked by pretreatment
of cells with Z-DEVD-fmk or in cells transfected with
mutant CDB3 (D45A, D205A) (6). Co-transfection exper-
iments showed that STS-mediated cleavage of CDB3 di-
minished its interaction with the N-terminal domain of
protein 4.2, confirming that such cleavage interferes
with the interaction of CDB3 with cytoskeletal proteins
(7). Active caspase 3 was observed in aged red cells but
not in young cells. This red cell caspase 3 could cleave
band 3 present in inside-out vesicles prepared from
young erythrocytes arguing in favor of a physiological
role of caspase 3 in aged erythrocytes.
Apoptosis is required to maintain the balance between cell
proliferation and cell death. Nuclear collapse and DNA frag-
mentation are universal features of apoptosis in nucleated
cells. However, the nucleus itself is not required for apoptosis,
since apoptotic stimuli induce apoptotic morphological features
in anucleate cells (1–3). The signaling events that culminate in
some of the key plasma membrane changes associated with cell
death in vivo, such as externalization of PS,1 operate inde-
pendently of the nucleus (3). While the process of apoptosis has
been studied in-depth in nucleated cells, the role of apoptosis
regulatory molecules in anucleate cells is poorly understood.
The anucleate mature circulating human erythrocyte is cleared
by macrophages after its 120-day life span. The senescent
erythrocyte shares at least one feature in common with nucle-
ated cells undergoing apoptosis. The externalization of PS on
the outer leaflet of the red cells results in recognition by macro-
phages probably through a receptor that engages PS (4). We
hypothesized that the circulating human erythrocyte poten-
tially shares part of the apoptotic machinery of nucleated cells,
and that this machinery may be triggered as a consequence of
red cell senescence, pathology such as in diseases like sickle
cell anemia, thalassemia, and oxidative insult to red cells.
Proteases play a critical role in the expression of mammalian
apoptosis. The caspases are a specialized family of cysteine-de-
pendent aspartate-directed proteases (5–7). The caspases rec-
ognize a tetrapeptide sequence on their substrates with an
aspartate residue at the fourth position. Caspase activation is
a critical event in the onset of apoptosis (5). Human caspase 3
is perhaps the most universal apoptosis mediator. It is present
in most mammalian cells (8). Its deletion by gene knockout
blocks neuronal death during brain development with conse-
quent lethality (9). Studies in our laboratory have demon-
strated that caspase 3 is present in mature human erythro-
cytes and activated by oxidative stress (10). Berg et al. (11)
have also demonstrated that caspases 3 and 8 are present in
mature human erythrocytes.
The cytoskeleton of an apoptotic cell undergoes profound
changes. Underlying these changes is the cleavage of many
cytoskeletal proteins by caspases. These include lamins (12,
13), gelsolin (14), actin (15), and fodrin (16). We speculate that
loss of anchorage of the lipid bilayer to the cytoskeleton could
also contribute to the loss of membrane integrity that is a
feature of erythrocyte senescence.
The two most abundant integral membrane proteins in the
human erythrocyte membrane are the sialoglycoprotein, glyco-
phorin and the anion exchanger, band 3. Both play a crucial
structural role in linking the bilayer with the spectrin-based
skeletal network. There are 1.2  106 copies of band 3 per cell
of which 40–60% is associated with the spectrin-based skele-
ton. Erythrocyte band 3 is a multifunctional protein with its N-
and C-terminal domains on the cytoplasmic face of the lipid
bilayer and 14 membrane spans (17–19). While the C-termi-
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nal 52 kDa membrane domain is responsible for anion trans-
port across the membrane, the 43 kDa N-terminal cytoplasmic
domain of band 3 (CDB3) plays a crucial structural role in
linking the bilayer with the spectrin-based skeletal network. It
functions as an anchoring site for the membrane-associated
cytoskeletal proteins ankyrin (20), protein 4.2 (21) and protein
4.1 (22); for the glycolytic enzymes glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (23), phosphofructokinase (24), and
aldolase (25); for hemoglobin (26, 27), for hemichromes (28) and
for the protein-tyrosine kinase p72syk (29). These interactions
regulate key elements of red cell structure and function includ-
ing cell flexibility (30), regulation of glucose metabolism, and
lifespan of the cell.
The non-erythroid counterpart of the major erythrocyte
membrane cytoskeletal protein spectrin is a substrate of
caspase 3. The caspase 3 cleavage sites on both - and -non-
erythroid spectrin (16, 17) have been mapped. Since little is
known about the molecular consequences of caspase activation
in red cells, we have chosen to address this question by at-
tempting to identify the substrates of caspase 3 in the mature
human erythrocyte. In the present study we have tested the
possibility that the cytoplasmic domain of band 3 may contain
caspase 3 cleavage sites. Proteolysis at these sites could poten-
tially alter each of the characteristics of red cell structure and
function regulated by the N-terminal CDB3. We demonstrate
for the first time that CDB3 is indeed a substrate for caspase 3.
We have identified two specific but non-conventional cleavage
sites of caspase 3 on CDB3. We also demonstrate that CDB3
expressed in HEK293 cells undergoes staurosporine-induced
degradation, which can be blocked by caspase 3 inhibitor; and
that this impairs the interaction of CDB3 with the cytoskeletal
protein 4.2. Defining CDB3 as a caspase substrate suggests a
mechanism by which caspase 3 activation in human erythro-
cytes under conditions such as oxidative stress, might lead to
important consequences such as uncoupling of the bilayer from
the underlying spectrin-based skeleton, and modulation of glu-
cose metabolism. That caspase 3 is likely to have a physiolog-
ical role in erythrocytes, is best supported by our observations
that active caspase 3 is present in aged red cells but not in
young cells, and that this red cell-derived caspase 3 is capable
of cleaving band 3 present in inside-out vesicles prepared from
young red cells. Our demonstration, for the first time, that
active caspase 3 is present in density-separated aged erythro-
cytes as opposed to young cells, is the best evidence that
caspase 3 is likely to play a physiological role in the mature
human erythrocyte.
EXPERIMENTAL PROCEDURES
Materials—The plasmids containing human caspase 3 and caspase 8
in pET 15b were gifts from Kevin Wang, University of Michigan, Ann
Arbor, MI. Band 3 cDNA was a gift from Joseph Casey, University of
Alberta, Edmonton. The caspase 3 inhibitor Z-DEVD-fmk was a product
of CN Biosciences, San Diego, CA, staurosporine (STS) was from Roche
Applied Science. Protein A/G-agarose, anti-caspase 3 antibody, and goat
anti-rabbit IgG linked to alkaline phosphatase were from Santa Cruz
Biotechnology, Santa Cruz, CA. Antibody against cleaved poly (ADP-
ribose) polymerase (PARP) was from Cell Signaling Technology,
Beverley, MA; anti-FLAG antibody was from Sigma Chemical Co., and
anti-His antibody was from Roche Applied Science.
Purification of Recombinant Caspase 3—Caspase 3 was expressed in
Escherichia coli BL21 (DE3) by induction with 0.5 mM isopropylthioga-
lactopyranoside (IPTG) at 25 °C and purified from the cytosol of the
expressed cells by affinity chromatography on Ni2-NTA-agarose
(Qiagen).
Cloning and Expression of the N-terminal Cytoplasmic Domain of
Band 3 (CDB3)—The gene encoding amino acids 1–390 of CDB3 was
amplified from band 3 cDNA by PCR using the primers 5-CGC GGA
TCC ATG GAG GAG CTG CAG GAT-3 (sense) and 5-GTA GCG GCG
CCG GAT ATC-3 (antisense), digested with BamHI (underlined) and
cloned in the vector pBAD-HisB (Invitrogen) between the BglII and
PvuII sites to generate the vector pBD101 encoding residues 1–390 of
band 3 with an N-terminal His tag. E. coli Top10/pBD101 was grown to
an OD600 of 0.6. Arabinose was added to a final concentration of 0.002%,
and growth was continued at 37 °C with shaking for 4 h. Cells were
harvested, reconstituted in 10 mM sodium phosphate, pH 7.4, 150 mM
NaCl (PBS), and kept at 70 °C overnight. Frozen cells were thawed
and treated with 1 mg/ml lysozyme, 5 mM DTT, 1% (v/v) Triton X-100
containing 1 g/ml DNase, 1 g/ml leupeptin, 1 g/ml aprotinin, 1
g/ml pepstatin, and 0.1 mM pefabloc for 30 min at 4 °C. The lysed cells
were centrifuged at 20,000  g for 30 min at 4 °C, and the supernatant
was loaded on a Ni2-NTA- agarose column equilibrated in 50 mM
sodium phosphate, pH 7.4, containing 0.5 M NaCl, 1% (v/v) Triton X-100
(buffer A). After washing the column with 100 mM imidazole in buffer A,
N-terminally His-tagged CDB3 was eluted with 200 mM imidazole in
buffer A.
Site-directed Mutagenesis—Site-directed mutagenesis was per-
formed by the principle of overlap extension PCR (31) using primers
detailed below. The first rounds of PCR were performed with primer
pairs a and b for one reaction and primer pairs c and d for the second
reaction. The second round of PCR was performed using the products of
the first round as templates and the primers a and d. Sequencing was
done on both strands to confirm incorporation of the mutations. Primers
b and c were respectively 5-ACAGCCACAGCCTACCACACC-3 and
5-GGTGTGGTAGGCTGTGGCTGT-3 for the mutation D45A; 5-AC-
AGCCACAGAATACCACACC-3 and 5-GGTGTGGTATTCTGTGGCT-
GT-3 for the mutation D45E; 5-GAGCAGGGAGCTGGGGGCACA-3
and 5-TGTGCCCCCAGCTCCCTGCTC-3 for the mutation D205A; 5-
GAGCAGGGAGAAGGGGGCACA-3 and 5-TGTGCCCCCTTCTCCCT-
GCTC-3 for the mutation D205E. Primers a and d were 5-CGCGGA-
TCCATGGAGGAGCTGCAGGAT-3 and 5-GTAGCGGCGCCGGATA-
TCACGCACCAG-3, respectively.
Cloning in pcDNA 3.1() and pFLAG-CMV-6b—The genes encoding
wild-type and mutant CDB3 were amplified by PCR with the primer
pair 5-CCA CCA TGG AGG AGC TGC AGG ATG ATT AT-3 (sense)
and 5-CCC AAG CTT CTA CAC AGG CAT GGC CAC TTC-3 (anti-
sense) and cloned into the vector pcDNA3.1() (Invitrogen) between the
EcoRV and HindIII (underlined) sites. An N-terminal Kozak se-
quence (-CCACC-) was introduced just upstream of the intiation codon
and a stop codon was incorporated in the antisense primer. All the
clones were sequenced. The protein 4.2 gene was amplified from the
protein 4.2 cDNA in pGEM-3z using the primer pair 5-AAGGATCCA-
TATGGGACAGGCACTGGGT-3 (sense) and 5-AGCTGATAGTTCAG-
GGGCTACCACGGT-3 (antisense), digested with BamHI (underlined)
and cloned between the BglII and EcoRV sites of pFLAG-CMV-6b
(Sigma Chemical Co.). The N-terminal 690 bp of the 4.2 gene (encoding
the N-terminal 230 amino acids) was amplified using the same sense
primer and the antisense primer 5-GGTGGGCAGGACCCTCTGCTC-
CTTGAG-3 and cloned as described above.
Preparation of Ghosts and Purification of CDB3—Human blood was
obtained from normal healthy volunteers. Ghosts were prepared by
washing cells thrice with 15 volumes of PBS followed by lysis in lysis
buffer (6.8 mM Na2HPO4, 2.25 mM NaH2PO4, pH 8.0 containing 10
g/ml pefabloc, 1 g/ml pepstatin, 10 g/ml aprotinin, and 1 g/ml
leupeptin). CDB3 was prepared from ghosts according to Bennett (32)
after chymotryptic cleavage from spectrin-depleted, acid-stripped vesi-
cles. Purified red cell CDB3 was used to raise polyclonal antibody in
rabbits. This antibody recognized the 43 kDa N-terminal cytoplasmic
domain of band 3 and all subfragments of this domain.
Preparation of Inside-Out Vesicles (IOV)—IOV were prepared by
treating ghosts with 30 volumes of 0.1 mM EGTA, pH 8.5 for 30 min at
37 °C, followed by centrifugation at 30,000  g for 20 min at 4 °C as
described by Korsgren and Cohen (33). Vesicles were washed once with
the same buffer.
Separation of Young and Aged Red Blood Cells on Percoll-Bovine
Serum Albumin Gradient—Density-dependent separation of red cells
was performed as described by Corsi et al. (34) with slight modifica-
tions. Briefly, the plasma was removed and erythrocytes were washed
three times with 10 mM sodium phosphate (pH 7.4), 150 mM NaCl, 5 mM
glucose (PBSG buffer), and layered at 25% hematocrit on a discontin-
uous Percoll (55–85%, v/v)-bovine serum albumin gradient (34) followed
by centrifugation at 1,500  g for 20 min at 20 °C. Young and aged
erythrocytes were collected separately from the 68 and 84% Percoll
layers respectively, and washed in PBSG buffer.
Western Blotting—Proteins were electrotransferred to polyvinylidene
difluoride (PVDF) membranes (Immobilon P, Millipore, Bedford, MA).
After blocking for 1 h with PBS-0.05% Tween 20 (PBS-T) containing 5%
nonfat dry milk (NFDM), the blots were washed in PBS-T and probed
with anti-CDB3 antibody (1:5,000) by incubation overnight at 4 °C.
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After three washes in PBS-T containing 0.5% NFDM, the blots were
incubated for 1 h with peroxidase-conjugated anti-rabbit IgG (1:2,000).
The blots were then washed three times with PBS-T containing 0.5%
NFDM and developed by chemiluminescence using the Lumiglo reagent
(Cell Signaling Technology, Beverley, MA). When performing Western
blotting for detection of caspases, 6  105 cells were pelleted and
freeze-thawed three times in 20 l of cell extraction buffer (50 mM
PIPES/NaOH (pH 6.5), 2 mM EDTA, 0.1% (w/v) CHAPS, 5 mM DTT, 20
g/ml leupeptin, 10 g/ml pepstatin, 10 g/ml aprotinin, 1 mM pefab-
loc). The lysates were centrifuged at 10,000  g for 5 min at 4 °C, and
the supernatants were collected for the detection of caspases.
In Vitro Proteolysis of CDB3 and Recombinant CDB3 by Caspase
3—Purified red cell CDB3 or recombinant CDB3 (1 g) was incubated
with purified recombinant caspase 3 (0.2 g) or caspase 8 (0.2 g) in 100
mM HEPES (pH 7.2) containing 10 mM DTT and 10% (v/v) glycerol at
25 °C for 120 min. The reaction was stopped by the addition of an equal
volume of SDS-PAGE sample buffer. Triplicate samples were subjected
to electrophoresis. One gel was stained with Coomassie Blue, whereas
two other samples were electroblotted onto polyvinylidene difluoride
membranes. One blot was subjected to Western blotting using anti-
CDB3 antibody. The other blot was used for N-terminal sequencing of
bands predicted to be derived from band 3 by development with anti-
band 3 antibody.
N-terminal Sequencing—After SDS-PAGE and electrotransfer, the
desired bands were cut out and subjected to N-terminal sequencing in
an Applied Biosystems protein sequencer at the protein sequencing
facility of Eurosequence, Groningen, The Netherlands.
Cell Culture and Transfection—The human embryonic kidney cell
line HEK293 was obtained from the National Centre for Cell Science,
Pune, India. Cells were grown in modified Eagle’s medium (MEM)
supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and
100 g/ml streptomycin at 37 °C with 5% CO2 in a humidified atmo-
sphere. Cells were transfected using the Polyfect reagent (Qiagen)
according to the manufacturer’s protocol. Briefly, cells (6  105/well)
were plated on 35-mm dishes and grown to 50–70% confluence. Cells
were incubated at 37 °C with Polyfect complex (formed by incubating 2
g of DNA and 20 l of Polyfect reagent in 100 l of serum-free MEM
for 15 min) in 2 ml of complete MEM. After 5 h of incubation, medium
was replaced with fresh MEM, and growth was permitted for another
36 h. For co-transfection experiments, 1 g of each DNA was used.
Immunoprecipitation Experiments—HEK293 cells after treatment
were lysed in lysis buffer containing 20 mM Tris-HCl, pH 8, 137 mM
NaCl, 10% glycerol, 1% Nonidet P-40, 20 mM NaF, 10 mM Na- -glyc-
erophosphate, 1 mM sodium orthovanadate, 1 mM pefabloc, and 10
g/ml aprotinin. The lysate was centrifuged at 15,000  g for 15 min at
4 °C. The supernatant, where required, was incubated overnight with
1:100 dilution of polyclonal anti-CDB3 antibody at 4 °C followed by
addition of 5 l of protein A/G-agarose. After incubation for 3 h at 4 °C,
the beads were pelleted, washed once in lysis buffer, boiled in SDS gel
denaturing buffer, and separated on SDS-polyacrylamide gels prior to
Western blotting.
Red cells were lysed with 5 volumes of 7.5 mM sodium phosphate
buffer (pH 7.4) containing 1 mM EDTA and 10 mM DTT. Immunopre-
cipitates were prepared by incubation overnight with 1:100 dilution of
anti-caspase 3 antibody (C-277, Santa Cruz Biotechnology) followed by
addition of protein A/G-agarose as described above.
Caspase 3 Activity Assay—DEVD-dependent protease activity was
determined using Ac-DEVD-pNA as substrate and the immunosorbent
caspase 3 activity assay kit from Roche Applied Science. Briefly,
caspase 3 was captured from lysates from 100-l erythrocytes (5%
hematocrit) in microtiter plates coated with anti-caspase 3 monoclonal
antibody. Following washing the plates, Ac-DEVD-pNA was added and
the released pNA was determined spectrophotometrically at 405 nm. A
pNA calibration curve was plotted from a pNA stock solution and the
caspase 3 activity was measured relative to this curve.
Apoptosis Induction—HEK293 cells were grown in 6-well plates and
transfected as described above. Apoptosis was induced by adding 10 M
STS followed by incubation for 24 h. Where indicated, cells were incu-
bated with Z-DEVD-fmk 1 h prior to STS treatment. After incubation,
cells were resuspended in SDS gel denaturing buffer, and proteins were
denatured at 100 °C for 3 min.
Cleavage of IOV with Caspase 3 Immunoprecipitates from Young and
Aged Erythrocytes—IOV were incubated at 37 °C with caspase 3 immu-
noprecipitates obtained from lysates of young and aged erythrocytes
(described above) in 20 mM HEPES, pH 7.5 containing 10 mM NaCl, 10
mM DTT, and 0.5% Nonidet P40. The assay was carried out in the
presence or absence of the caspase 3 inhibitor Z-DEVD-fmk (10 M).
Samples were separated on SDS-12% polyacrylamide gels, electrotrans-
ferred onto polyvinylidene difluoride membranes, and probed with poly-
clonal anti-CDB3 antibody as described earlier.
RESULTS
In Vitro Degradation of CDB3 by Recombinant Caspase
3—We have previously shown that mature human erythrocytes
contain caspase 3, and that caspase 3 can be activated under
oxidative stress (10). Cytoskeletal proteins such as spectrin
have previously been demonstrated to be substrates of caspase
3 (16, 17). Since the major erythrocyte membrane integral
membrane protein band 3 plays a pivotal role in regulating
structure and function of the mature human erythrocyte, this
study was undertaken to test the possibility that cytosolic
domains of band 3 could be substrates of caspase(s). The N-
terminal cytosolic domain of band 3 (CDB3) has been chosen as
the starting point of these investigations. CDB3 was purified
from red cells and tested as a substrate of caspase 3 by incu-
bating with recombinant purified caspase 3. Cleavage of CDB3
was observed. Two bands migrating with Mr 18 and 21 were
reproducibly obtained (Fig. 1A, lane b). The appearance of
these bands was blocked when CDB3 was pretreated with the
caspase 3 inhibitor Z-DEVD-fmk (Fig. 1A, lane c). Controls in
which no caspase 3 had been added did not show significant
degradation of CDB3 (Fig. 1A, lane a). The two cleaved frag-
ments cross-reacted with anti-CDB3 antibody when subjected
to Western blotting (data not shown). This confirmed that they
were derived from CDB3. These bands were subjected to N-
terminal sequencing. The N-terminal sequences mapped to the
sequences 46YHTTS and 206GGTEG for the bands migrating
with Mr 18 and 21, respectively. From these sequences we
inferred that caspase 3 cleavage had occurred on the C-termi-
nal side of the sequences TATD45 and EQGD205, respectively.
On the other hand, incubation of red cell CDB3 with recombi-
nant caspase 8 did not result in any cleavage of CDB3 (data not
shown), suggesting that cleavage was specific for caspase 3. In
order to facilitate mapping of cleavage sites by mutational
analyses, further experiments of in vitro cleavage of CDB3 by
caspase 3 were performed using recombinant His-tagged
CDB3. To reconfirm that caspase 3 cleavage sites mapped to
TATD45 and EQGD205, His-tagged CDB3 was incubated with
caspase 3. Recombinant His-tagged CDB3 migrated with an
apparent molecular mass of 60 kDa on SDS gels (Fig. 1, panel
B, band a). The migration of cleaved fragments was also slower
and reflected anomaly. The reason for this is unclear. However,
the migration pattern was reproducible. The anomaly may
possibly be attributed to the fact that CDB3 exhibits a highly
elongated morphology (35) combined with the addition of the
N-terminal hexahistidine tag. Nevertheless, incubation of pu-
rified His-tagged recombinant CDB3 with caspase 3 gave two
cleaved fragments of apparent molecular masses 25 and 22
kDa reproducibly (Fig. 1B, bands d and e). These bands were
confirmed to be derived from CDB3 by Western blotting with
anti-CDB3 antibody (data not shown). Cleavage at the two sites
TATD45 and EQGD205 were predicted to generate fragments of
size 4.5, 17.3, and 21.1 kDa corresponding to residues 1–45,
46–205, and 206–390 respectively (Fig. 1, panel E and Table I).
N-terminal sequencing of the bands e and d observed on SDS-
PAGE showed that they were indeed derived from cleavage at
TATD452 YYHTTS and EQGD2052 GGTEG, respectively. As
expected, neither of these bands gave a positive reaction with
anti-His antibody (Fig. 1, panel C). Any proteolytic fragment
corresponding to residues 1–45 along with the hexahistidine
tag with a predicted molecular mass of 4.5 kDa was, as ex-
pected, not visible on 10 or 12% polyacrylamide SDS gels. The
bands derived from red cell CDB3 migrated differently from
those derived from recombinant CDB3 despite the absence of
the His tag in both cases. This may be due to the C terminus of
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red cell-derived CDB3 (obtained by chymotryptic cleavage) be-
ing different from that of the recombinant CDB3 (i.e. residue
390). In summary, red cell-derived CDB3 and recombinant
CDB3 behaved similarly with respect to their recognition by
caspase 3 as substrate. Caspase 8, on the other hand, was
unable to cleave CDB3 (data not shown).
Proteolysis of CDB3 by Caspase 3 in the Presence of the
Inhibitor Z-DEVD-fmk—The cleavage sites on CDB3 mapped
by us did not match the preferred caspase 3 consensus se-
quence DXXD (36, 37). In order to confirm the specificity of
caspase 3-mediated cleavage, incubations of CDB3 with
caspase 3 were carried out in the presence of different concen-
trations of the caspase 3-specific inhibitor Z-DEVD-fmk. A dose-
dependent effect of the inhibitor in blocking caspase 3-medi-
ated proteolysis was observed (Fig. 1D). Complete inhibition of
caspase 3-mediated cleavage was observed at an inhibitor con-
centration of 10 M. This confirmed the specificity of cleavage
by caspase 3.
Proteolysis of Site-specific Mutants of CDB3 by Caspase
3—Site-specific mutants were generated in which the site
TATD45 was mutated to TATA and the site EQGD205 was
mutated to EQGA individually and in combination. Caspase 3
specifically cleaves at the C-terminal end of aspartate residues
and it was surmised that neither of the mutants would be
cleaved at the sites of mutation by caspase 3. This was indeed
found to be the case. Cleavage by caspase 3 was blocked at each
of the mutated sites and products of altered size were obtained
(Fig. 1B). CDB3 harboring the D45A mutation (CDB3
[D45A])gave the bands d and c. Predictably, from the N-termi-
nal sequence GGTEG of band d, we could deduce that cleavage
had occurred on the C-terminal side of Asp205. Band e, gener-
ated in the wild type from cleavage on the C-terminal side of
Asp45 encompassing residues 46–205 was expectedly absent in
caspase-cleaved CDB3[D45A]. Another fragment (residues
1–205) of calculated Mr 21.8 carrying the N-terminal His tag
could be predicted (Table I). We observed the appearance of
band c migrating with Mr 35 and carrying the His tag (as
probed by Western blotting with anti-His antibody (Fig. 1C)),
suggesting that this probably represented the fragment of
CDB3 encompassed by residues 1–205 along with the N-termi-
nal hexahistidine tag. Band c was, as expected, also positive on
Western blots probed with anti-CDB3 antibody (data not
shown). No other band was positive when probed with anti-His
antibody (Fig. 1C) excluding the possibility that the extreme N
terminus was present in any of the other bands. Anomaly in
migration was therefore assumed to be the reason for obtaining
a band of Mr 35. This anomaly was most pronounced on SDS
gels for bands a and c, both of which retain the extreme N-
terminal 45 residues. This suggested that residues 1–45 of
CDB3 probably encompass the critical determinants of an elon-
FIG. 1. Cleavage of CDB3 in vitro by caspase 3. Panel A, purified red cell CDB3 was incubated without (lane a) or with (lanes b and c)
recombinant caspase 3 in the absence (lane b) or in the presence (lane c) of Z-DEVD-fmk (10 M) at 37 °C for 4 h. Recombinant (N-terminal
hexahistidine-tagged) wild type (WT) (panels B, C, and D) or mutant (panels B and C) CDB3 expressed in E. coli were either left untreated or
treated with caspase 3 for 2 h either in the absence (panels B and C) or in the presence (panel D) of caspase 3 inhibitor Z-DEVD-fmk at different
concentrations as indicated. The samples were then denatured by SDS gel denaturing buffer, separated on SDS-polyacrylamide gels, followed by
staining with Coomassie Blue (panels A, B, and D) or probing with anti-His antibody after electroblotting (panel C). Panel E is a diagrammatic
representation of the caspase 3 cleavage sites (indicated by arrows) identified in CDB3 by N-terminal sequencing.
TABLE I
Predicted and deduced caspase 3 cleavage sites in the cytoplasmic domain of band 3
Recombinant N-terminal sequenceobtained
Assumed caspase
cleavage site
Predicted
mol. wt.
Mol. wt. on
SDS-PAGE
kDa kDa
Wild type YHTTS and GGTEG TATD45YHTTS and
EQGD205GGTEG
4.5, 17.3, and
21.1
Two bands of 22 and 25 (e and d,
respectively)a
Mutant D45A GGTEG EQGD205GGTEG 21.8 and 21.1 35 and 25 (c and d, respectively)
Mutant D205A YHTTS TATD45YHTTS 4.5 and 38.4 One band of 40 (b)
Mutant D45A, D205A N.D.b None 42.9 One band of 60 (a)
a a, b, c, d, and e refer to the bands depicted in Fig. 1.
b N.D., not determined.
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gated conformational state of CDB3 when expressed in E. coli
leading to its anomalous migration on SDS gels. When
CDB3[D205A] was cleaved by caspase 3 only one proteolyti-
cally derived band b (Mr 40) was visible on SDS gels. The
predicted size of the fragment encompassing residues 46–390
was 38.4 kDa (Table I). The N-terminal sequence of band b
mapped to the sequence YHTTS enabling us to infer that cleav-
age had occurred on the C-terminal side of Asp45. Unlike the
wild type CDB3, a proportion of uncleaved CDB3 was always
present in both the mutants even upon prolonged incubation
with caspase 3. The reason for this is unclear at present.
CDB3[D45A/D205A] was resistant to cleavage by caspase 3,
confirming that Asp45 and Asp205 represent the two caspase 3
cleavage sites on CDB3. Mutants D45E and D205E behaved
identically with D45A and D205A, respectively (data not
shown).
Cleavage of CDB3 in Cells Undergoing Apoptosis—In order
to examine whether CDB3 undergoes caspase 3-mediated
cleavage in vivo, we transfected HEK293 cells with CDB3.
CDB3 rather than intact band 3 was chosen for transfection in
order to facilitate the confirmation of the caspase 3 cleavage
sites by mutational analysis. Lysates from transiently trans-
fected cells were probed with anti-CDB3 antibody. Western
analysis demonstrated that CDB3 was expressed in transfected
cells (Fig. 2A). Immunoblot analysis showed an apparent het-
erogeneity in migration of CDB3 on SDS gels (Mr ranging from
40 to 43). Similar heterogeneity in migration of CDB3 has also
been reported by Bennett (32). Apoptosis was induced by treat-
ment with STS (10 M) for different periods of time. Cells after
STS treatment for 24 h did not lose their membrane integrity
since they did not stain with the dye trypan blue. This indi-
cated that the cells were undergoing apoptosis rather than
necrosis. Lysates from untreated cells or cells treated with STS
were analyzed by SDS-PAGE followed by Western blotting
using polyclonal anti-CDB3 antibody. STS-treated cells showed
the time-dependent appearance of two bands which were cross-
reactive with anti-band 3 antibody (Fig. 2A) and absent in
untreated cells. STS-treated untransfected cells did not show
these bands (data not shown). To examine whether caspase 3
was involved in the generation of these bands, cells were
treated with the cell-permeable caspase 3 inhibitor Z-DEVD-
fmk for 1 h prior to STS treatment. The appearance of both
these bands was blocked in cells that had been treated with
Z-DEVD-fmk (Fig. 2B). This suggested that these bands were
derived from caspase 3 activation. To verify whether the two
aspartate residues 45 and 205 (which were identified in vitro),
represent the apoptosis-dependent caspase 3 cleavage sites of
CDB3 in vivo, we performed experiments in STS-treated cells
expressing CDB3[D45A/D205A]. Mutant CDB3 did not show
any degradation on exposure to STS (Fig. 2B), suggesting that
Asp45 and Asp205 represent STS-induced caspase 3 cleavage
sites. Caspase 3 activation, a hallmark of apoptosis, was fol-
lowed by Western blotting to detect the activated form of
caspase 3 (17 kDa). (Fig. 2D). Caspase 3 activation was also
supported by the observation that there was a time-dependent
increase in the appearance of cleaved PARP, a caspase 3 sub-
strate (Fig. 2C).
Interaction of Protein 4.2 with CDB3 in HEK293 Cells Un-
dergoing Apoptosis—Protein 4.2 was chosen as one of the nat-
ural binding partners of CDB3. Attempts were made to study
the interaction of full-length protein 4.2 with CDB3. However,
the level of expression of protein 4.2 was very low as observed
by Western blotting with anti-FLAG antibody. Moreover, the
expressed protein 4.2 was readily degraded, possibly by pro-
teases, during preparation of cell lysates. Since our previous
work has demonstrated that an N-terminal 23-kDa polypeptide
derived from protein 4.2 interacts with CDB3 (38), we chose to
study the binding of the N-terminal domain of protein 4.2
encompassing the first 230 amino acid residues of protein 4.2
carrying a FLAG epitope (designated as C1), in STS-treated
HEK293 cells in order to analyze whether the ability of CDB3
to interact with its natural binding partners is compromised in
HEK293 cells undergoing apoptosis. Lysates were prepared
from cells transfected with FLAG-C1 (24 kDa) or CDB3 alone
or co-transfected with FLAG-C1 and CDB3. The cell-free su-
pernatant was incubated with polyclonal anti-CDB3 antibody,
followed by pull-down with protein A/G-agarose. Western blot-
ting of the immunoprecipitates with anti-FLAG antibody dem-
onstrated that FLAG-tagged C1 could be pulled down by anti-
CDB3 antibody in the co-transfected cells only (Fig. 3A, lane 4).
Immunoprecipitates obtained from cell lysates transfected with
CDB3 (Fig. 3A, lane 1) or with C1 (Fig. 3A, lane 2) alone, did not
develop any band with anti-FLAG antibody. This clearly dem-
onstrated the interaction of C1 with CDB3 in HEK293 cells
after cotransfection. Lysates were also prepared from cells
transfected with C1 alone and pulled down with protein A/G-
agarose in order to rule out the possibility that C1 could be
pulled down nonspecifically by protein A-agarose (Fig. 3A, lane
1). When HEK293 cells co-transfected with C1 and CDB3, were
treated with STS, immunoprecipitates from cell lysates showed
a significant reduction in the intensity of the band correspond-
ing to C1 when developed with anti-FLAG antibody (Fig. 3A,
lane 5), suggesting that there was a reduction of C1-CDB3
interaction in HEK293 cells undergoing STS-induced caspase
3-mediated apoptosis. The interaction was restored in cells
pretreated with the cell-permeable caspase 3 inhibitor
Z-DEVD-fmk prior to STS treatment (Fig. 3B) indicating a role
of caspase 3. This was further supported by the observation
that C1-CDB3 interaction was not affected by STS treatment
(Fig. 3A, lanes 6 and 7) when the mutant CDB3[D45A/D205A]
was used in co-transfection experiments. Finally, Western blot-
ting of lysates obtained from C1-transfected STS-treated cells
with anti-FLAG antibody showed that C1 itself is resistant to
caspase 3-mediated cleavage (Fig. 3C). No degradation of C1
FIG. 2. CDB3 is cleaved during apoptosis in a time-dependent
manner. HEK293 cells expressing wild-type CDB3 (panels A–D) or
CDB3[D45A/D205A] (panel B) were treated with staurosporine (10 M)
for the indicated periods of time (panels A, C, and D) or for 24 h (panel
B, where indicated). Equivalent amounts of total cell lysates were
separated on SDS-polyacrylamide gels and CDB3 or its cleaved prod-
ucts (indicated by arrows) were detected in Western blots using a rabbit
polyclonal antibody raised against CDB3. Cleaved PARP (89 kDa) was
detected by Western blotting using antibody against cleaved PARP
(panel C), procaspase 3, and caspase 3 (32 and 17 kDa, respectively)
were detected by antibody against caspase 3 (panel D).
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was detected on immunoblots even when probed with poly-
clonal anti-4.2 antibody (data not shown).
Role of Endogenous Red Cell Caspase 3 in the Cleavage of
Band 3—Based on our previous observations that oxidative
stress could activate caspase 3 in mature human erythrocytes
(10) we argued that caspase 3 could possibly be activated dur-
ing erythrocyte senescence and that this activation could play
a role in red cell senescence by cleavage of band 3. During the
course of its 120-day life span, the erythrocyte undergoes a
time-dependent increase in cell density. This has been the basis
of the widely used method of density-dependent separation of
young and old erythrocytes (34, 39, 40). In order to test our
hypothesis that caspase 3 activation could play a role in red cell
senescence, young and old human red blood cells were sepa-
rated on a Percoll gradient. Cells were lysed and the cytosol
were used for the analysis of soluble intracellular caspase 3.
Erythrocyte cytosol from old red blood cells were found to
contain detectable levels of activated, cleaved caspase 3 as
assessed by Western blotting (Fig. 4A). On the other hand,
cleaved caspase 3 could not be detected in lysates from young
red blood cells, although procaspase 3 was visible on Western
blots. This was further supported by assaying the caspase
activity using the substrate Ac-DEVD-pNA. Caspase 3 cap-
tured from lysate prepared from 100 l aged erythrocytes (of
5% hematocrit) released 650  40 pmol of pNA/h. This was
10-fold more than the activity that could be detected in young
erythrocyte lysates. In order to test whether endogenous red
cell caspase 3 could cleave red cell band 3, IOV were prepared
from young erythrocytes. Caspase 3 was immunoprecipitated
from the lysates of old erythrocytes with anti-caspase 3 anti-
body and the immunoprecipitate was incubated with IOV from
young erythrocytes. Considerable fragmentation of band 3 was
observed (Fig. 4B, lane b) in IOV incubated in the presence of
red cell caspase 3 with the appearance of bands ranging in size
18–70 kDa cross-reactive with anti-band 3 antibody. This was
blocked when IOV were pretreated with the caspase 3 inhibitor
Z-DEVD-fmk (Fig. 4B, lane c). Incubation of IOV with the
immunoprecipitate derived from young red cells, did not show
significant fragmentation of band 3 (Fig. 4B, lane a).
DISCUSSION
Proteolysis by caspases plays a central role in the execution
of apoptosis in different cell types. Based on the premise that
red cells though anucleated, undergo senescence, recognition
by macrophages and removal from the circulation over the
course of a 120-day life span, we sought to investigate the
potential role of caspases on membrane remodeling in the
mature human red cell. In our previous studies we have dem-
onstrated that red cells contain caspase 3 (10), the central
player in most apoptotic signaling pathways, and that caspase
3 is activated in response to oxidative stress. These findings
prompted us to look for potentially crucial caspase 3 substrates.
Through interactions with a diverse array of proteins, CDB3
regulates among others, cell shape, glucose metabolism, ion
transport, and cell clearance from the circulation. Considering
its central role, we asked the question whether CDB3 contains
caspase 3 cleavage sites. CDB3 was purified from mature hu-
man erythrocytes and used as a substrate for recombinant
caspase 3. It was cleaved by caspase 3 to give two major
fragments which were sequenced from the N terminus. This
enabled us to deduce that cleavage occurs on the C-terminal
side of the two sites: TATD45 and EQGD205. In order to conduct
further detailed studies, recombinant CDB3 was expressed in
E. coli and used as a substrate for recombinant caspase 3. The
same sites of cleavage could be demonstrated with recombinant
CDB3 as substrate. The deduced two sites fit the preferred P4
but not P1 consensus for caspase 3 (41). These sites represent
a growing list of cleavage sites of caspase 3, which do not fit the
DXXD consensus motif (42–44). This was further confirmed by
the following experiments: (1) when caspase 3 inhibitor was
added, the cleavage of CDB3 by caspase 3 could be blocked; and
(2) site-directed mutagenesis of Asp45 and Asp205 (to either Ala
or Glu) could prevent the caspase 3-mediated cleavage of
FIG. 3. Interaction of CDB3 with a protein 4.2-derived domain
in HEK293 cells. Panel A, HEK293 cells were transfected with C1
alone (lanes 1 and 2), or CDB3 alone (lane 3) or with C1 and CDB3
(lanes 4 and 5) or with C1 and CDB3[D45A/D205A] (lanes 6 and 7).
Cells were either left untreated (lanes 1–4 and 6) or treated with
staurosporine (10 M) for 24 h (lanes 5 and 7). Cells were lysed, lysates
were incubated without (lane 1) or with (lanes 2–7) anti-CDB3 antibody,
followed by immunoprecipitation with protein A-agarose. Immunopre-
cipitates were subjected to SDS-PAGE followed by Western blotting
with anti-FLAG antibody. Panel B, cells co-transfected with C1 and
CDB3 were left untreated (lanes 1 and 2) or pretreated with caspase 3
inhibitor (Z-DEVD-fmk) (lane 3), followed by staurosporine treatment
(lanes 2 and 3). Immunoprecipitation and Western blotting with anti-
FLAG antibody were carried out as described under panel A. Panel C,
cells, not transfected (lane 1) or transfected with C1 alone (lanes 2 and
3), were left untreated (lanes 1 and 2) or treated with staurosporine
(lane 3) for 24 h, followed by lysis and Western blotting using anti-
FLAG antibody.
FIG. 4. Detection of active caspase 3 in red cells and cleavage
of band 3 by red cell caspase 3. Panel A, cytosol obtained from young
(lanes a and c) and old erythrocytes (lanes b and d) were incubated
overnight without (lanes a and b) or with (lanes c and d) caspase 3
antibody, followed by pull-down with protein A/G-agarose. The immu-
noprecipitates were separated on SDS-polyacrylamide gels prior to
Western blotting with anti-caspase 3 antibody. The blot is representa-
tive of similar results obtained with three samples from three different
volunteers. Panel B, inside-out vesicles from young erythrocytes were
incubated with caspase 3 immunoprecipitates (obtained as described
under panel A) from young (lane a) or aged erythrocyte cytosol (lanes b
and c) in the absence (lanes a and b) or in the presence (lane c) of the
caspase 3 inhibitor Z-DEVD-fmk for 4 h at 37 °C. Samples were sepa-
rated on SDS-polyacrylamide (12%) gels, followed by Western blotting
using polyclonal anti-CDB3 antibody. The blot is representative of
similar results obtained in three different experiments.
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CDB3. The crystal structure of CDB3 suggests that residues
1–54 and 202–211 represent regions in CDB3 with segmental
flexibility (45). These regions would therefore be likely to be
accessible for caspase-mediated proteolysis. The glycolytic en-
zymes (GAPDH, aldolase, and phosphofructokinase) (23–25)
bind to the extreme N terminus of CDB3. Caspase-mediated
cleavage of CDB3 at position 45 would be sufficient to disrupt
each of these interactions. The binding site of protein 4.2 on
CDB3 may involve, among other residues, Glu-40, since muta-
tion at Glu-40 leads protein to 4.2 deficiency and hereditary
spherocytosis (46). Cleavage at Asp-45 and Asp-205 could
therefore be sufficient to abrogate protein 4.2 binding. In order
to analyze whether CDB3 could be cleaved by caspase 3 in vivo,
HEK293 cells were transiently transfected with CDB3, since
red cells are not amenable to transfection. To investigate the
apoptosis-induced fragmentation of CDB3, we treated tran-
siently transfected HEK293 cells with the protein kinase in-
hibitor STS, which is known to induce apoptosis in many cell
types (47, 48). We observed that these cells were undergoing
apoptosis rather than necrosis. Immunoblot analysis of STS-
treated cell lysates showed the partial degradation of CDB3 as
well as formation of two anti-band 3 antibody cross-reactive
bands in a time-dependent manner. The kinetics of formation
of these two fragments from CDB3 was parallel to that of the
fragmentation of PARP, a widely recognized caspase 3 sub-
strate. There was a concomitant increase in the formation of
cleaved caspase 3 also. The specificity of caspase 3-mediated
proteolysis was confirmed by the observation that pretreat-
ment with Z-DEVD-fmk prior to STS treatment could block the
cleavage of CDB3. This was further confirmed by the fact that
HEK 293 cells expressing mutant CDB3[D45A/D205A] did not
show any cleavage of CDB3 upon STS treatment.
Protein 4.2, a 72 kDa peripheral membrane protein binds
band 3 (21) and stabilizes the linkage of the cytoskeleton to the
lipid bilayer. Protein 4.2 associates with band 3 and controls
the lateral and rotational mobility of band 3 oligomers (49).
From in vitro analysis we have previously demonstrated that
the N-terminal domain of protein 4.2 is one of the domains
critical for the protein 4.2-CDB3 interaction (38). It was there-
fore tempting to speculate that the induction of caspase 3-me-
diated apoptosis may lead to the disruption of band 3-protein
4.2 interaction. In order to study the interaction of protein 4.2
with CDB3 in vivo, we co-transfected HEK293 cells with
FLAG-tagged C1 (encompassing the N-terminal 230 amino
acid residues of protein 4.2) and CDB3. Immunoprecipitates
obtained using anti-CDB3 antibody from lysates of cells ex-
pressing both CDB3 and C1, showed the presence of Flag-
tagged C1 by Western analysis. This demonstrated the in vivo
interaction between C1 and CDB3 in HEK293 cells. STS treat-
ment after co-transfection significantly diminished such inter-
action between C1 and CDB3. The interaction was not abol-
ished since a proportion of intact band 3 was invariably present
in STS-treated cells. Interaction could be restored when the
caspase 3 inhibitor Z-DEVD-fmk was used prior to STS treat-
ment. This was evidence of the STS-induced caspase 3-medi-
ated cleavage of CDB3 compromising its function of serving as
the binding site for cytoskeletal proteins.
Finally, it was of utmost importance to demonstrate that
active caspase 3 is present in human erythrocytes and that it
indeed cleaves red cell band 3. Considering that aged erythro-
cytes show reduced glutathione levels, and our earlier obser-
vations that oxidative stress activates caspase 3 in mature
human erythrocytes, we asked the question whether caspase 3
activation was a feature associated with erythrocyte senes-
cence. Caspase 3 was indeed observed to be activated in aged
red cells both by Western analysis, which showed the presence
of cleaved caspase 3 and by spectrophotometric activity assay.
Lysates from aged or young red cells were used as source of
caspase 3 and tested in terms of their ability to degrade red cell
band 3. Band 3 present in IOV from young erythrocytes was
found to be cleaved by anti-caspase 3 immunoprecipitates of
lysates derived from aged red cells only, further supporting the
argument of a possible physiological role of active caspase 3 in
erythrocyte aging. Band 3 degradation mediated by caspase 3
could serve as a senescence signal for the removal of aged cells
from the circulation. The cleavage pattern of band 3 showed the
presence of several bands of different sizes. This was not sur-
prising, since, in addition to the sites present in CDB3, other
cytosolic domains of band 3 could contain caspase 3 cleavage
sites, which are yet to be identified.
In conclusion, we have demonstrated for the first time the
cleavage of any of the isoforms of the anion exchanger band 3
by caspase 3. Red cell CDB3 is cleaved by caspase 3 in vivo at
two non-conventional sites TATD45 and EQGD205, and this
weakens CDB3-protein 4.2 interactions. The cleavage sites
identified in this study are specific for the erythroid anion
exchanger AE1 and are not conserved in AE2 and AE3. The
mature human erythrocyte is devoid of a nucleus and mito-
chondria. Nevertheless, we and other workers (10) have shown
that at least some players of the apoptotic program known in
nucleated cells are present in the mature human erythrocyte.
We have also shown that caspase 3 can be activated under
oxidative stress. It is therefore interesting to speculate that
caspases when activated in the mature human erythrocyte
could participate in the degradation of crucial erythrocyte pro-
teins involved in the maintenance of shape and function. Ex-
emplary of this is our demonstration for the first time that
caspase 3-mediated cleavage of CDB3 could disrupt its inter-
action with the peripheral membrane protein 4.2, a finding,
which could have potentially serious consequences under con-
ditions of stress or pathology, and possibly during senescence.
Of foremost importance is our observation that active caspase
3 from aged erythrocytes can cleave red cell band 3, strongly
suggesting that caspase-mediated cleavage of substrates such
as band 3 is likely to play a crucial role in erythrocyte senes-
cence. These findings open avenues of future investigation on
the consequences of caspase 3-directed cleavage on the many
functions associated with the cytoplasmic domains of band 3.
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